GlassScriptPhysician profile
Harish Saiganesh
NPI 1790214070
$2,492.33
in general payments reported to CMS, 2019-2025
37 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $121 · 2023: $412 · 2024: $1,166 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,183 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,183.49 |
| Education | $188.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $340.71 | 2023-2025 | Opdivo, Opdualag, Augtyro |
| Incyte Corporation | $240.38 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $150.97 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Abbvie INC. | $132.77 | 2022-2024 | Venclexta |
| Celgene Corporation | $124.10 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Gilead Sciences, INC. | $112.95 | 2024-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $91.25 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Sobi, INC | $84.36 | 2024-2025 | |
| Daiichi Sankyo INC. | $81.24 | 2023-2025 | Injectafer, Datroway, Enhertu |
| Genzyme Corporation | $78.29 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $77.32 | 2023-2025 | Qinlock, Romvimza |
| Taiho Oncology, INC. | $71.84 | 2024-2025 | |
| Pfizer INC. | $67.34 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $66.86 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $61.68 | 2024-2025 | Libtayo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $61.40 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.19 | 2024-2025 | |
| Stemline Therapeutics INC. | $56.52 | 2023 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $55.77 | 2024 | Somatuline Depot, Onivyde |
| Glaxosmithkline, LLC. | $52.26 | 2023-2024 | Ojjaara |
| Genentech USA, INC. | $51.84 | 2024-2025 | Tecentriq, Columvi, Lunsumio |
| Tempus Ai, INC | $37.67 | 2024 | Xt Cdx |
| Janssen Biotech, INC. | $35.33 | 2025 | |
| Tersera Therapeutics LLC | $34.91 | 2024 | Zoladex |
| Beigene USA, INC. | $29.94 | 2024 | Brukinsa |
| Geron Corporation | $24.08 | 2024 | Rytelo |
| Seagen INC. | $22.59 | 2023 | Tukysa |
| Array Biopharma INC | $21.94 | 2024 | Lorbrena |
| Exelixis INC. | $20.99 | 2023 | Cabometyx |
| Medtronic, INC. | $20.58 | 2023 | Osteocool Rf Ablation System |
| Amgen INC. | $20.56 | 2022 | |
| Beone Medicines USA, INC. | $19.27 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $19.03 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $18.34 | 2024 | Cosela |
| Alexion Pharmaceuticals, INC. | $17.96 | 2025 | Ultomiris |
| Astellas Pharma US INC | $16.22 | 2024 | Padcev |
| Pharmaessentia USA Corporation | $15.88 | 2025 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harish Saiganesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.